The Misuse of Drugs Regulations 2001

Regulation 3

SCHEDULE 1 U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 23, 26 AND 27

1.  The following substances and products, namely - U.K.

(a) Bufotenine

• Cannabinol

• Cannabinol derivatives not being dronabinol or its stereoisomers

• Cannabis and cannabis resin

• Cathinone

• Coca leaf

• Concentrate of poppy-straw

• Eticyclidine

• Etryptamine

• [F1 Fungus (of any kind) which contains psilocin or an ester of psilocin]

• Lysergamide

• Lysergide and otherN-alkyl derivatives of lysergamide

• Mescaline

• Methcathinone

• Psilocin

• Raw opium

• Rolicyclidine

• Tenocyclidine

• 4-Bromo-2,5-dimethoxy-a-methylphenethylamine

• N,N-Diethyltryptamine

• N,N-Dimethyltryptamine

• 2,5-Dimethoxy-a,4-dimethylphenethylamine

• N-Hydroxy-tenamphetamine

• 4-Methyl-aminorex

(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(c) the following phenethylamine derivatives, namely—

• Allyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

• 2-Amino-1-(3,4-dimethoxyphenyl)ethanol

• Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 4-Bromo-b,2,5-trimethoxyphenethylamine

• N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

• Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

• 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine

• 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

• 2-(1,4-Dimethoxy-2-naphthyl)ethylamine

• 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

• N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

• 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

• 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

• a,a-Dimethyl-3,4-methylenedioxyphenethylamine

• a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine

• Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine

• 4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine

• 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

• 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

• 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

• 2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

• b-Methoxy-3,4-methylenedioxyphenethylamine

• 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine

• 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine

• 2-(a-Methyl-3,4-methylenedioxyphenethylamino)ethanol

• a-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

• N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

• O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

• a-Methyl-4-(methylthio)phenethylamine

• b,3,4,5-Tetramethoxyphenethylamine

• b,2,5-Trimethoxy-4-methylphenethylamine

(d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;

(e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -

(i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii) by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi) by replacement of theN-propionyl group by another acyl group;

(f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—

(i) by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

(iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

(v) by formation of an N-oxide or of a quaternary base.

Textual Amendments

F1 Words in Sch. 1 inserted (18.7.2005) by The Misuse of Drugs (Amendment) (No. 2) Regulations 2005 (S.I. 2005/1653), regs. 1, 2(3)

2.  Any stereoisomeric form of a substance specified in paragraph 1. U.K.

3.  Any ester or ether of a substance specified in paragraph 1 or 2. U.K.

4.  Any salt of a substance specified in any of paragraphs 1 to 3. U.K.

5.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5. U.K.

Regulation 3

SCHEDULE 2 U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 21, 23, 26 AND 27

1.  The following substances and products, namely— U.K.

• Acetorphine

• Alfentanil

• Allylprodine

• Alphacetylmethadol

• Alphameprodine

• Alphamethadol

• Alphaprodine

• Anileridine

• Benzethidine

• Benzylmorphine (3-benzylmorphine)

• Betacetylmethadol

• Betameprodine

• Betamethadol

• Betaprodine

• Bezitramide

• Carfentanil

• Clonitazene

• Cocaine

• Desomorphine

• Dextromoramide

• Diamorphine

• Diampromide

• Diethylthiambutene

• Difenoxin

• Dihydrocodeinone O-carboxymethyloxime

• [F2 Dihydroetorphine]

• Dihydromorphine

• Dimenoxadole

• Dimepheptanol

• Dimethylthiambutene

• Dioxaphetyl butyrate

• Diphenoxylate

• Dipipanone

• Dronabinol

• Drotebanol

• Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine

• Ethylmethylthiambutene

• Etonitazene

• Etorphine

• Etoxeridine

• Fentanyl

• Furethidine

• Hydrocodone

• Hydromorphinol

• Hydromorphone

• Hydroxypethidine

• Isomethadone

• Ketobemidone

• Levomethorphan

• Levomoramide

• Levophenacylmorphan

• Levorphanol

• Lofentanil

• Medicinal opium

• Metazocine

• Methadone

• Methadyl acetate

• Methyldesorphine

• Methyldihydromorphine (6-methyldihydromorphine)

• Metopon

• Morpheridine

• Morphine

• Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives

• Myrophine

• Nicomorphine

• Noracymethadol

• Norlevorphanol

• Normethadone

• Normorphine

• Norpipanone

• Oxycodone

• Oxymorphone

• Pethidine

• Phenadoxone

• Phenampromide

• Phenazocine

• Phencyclidine

• Phenomorphan

• Phenoperidine

• Piminodine

• Piritramide

• Proheptazine

• Properidine

• Racemethorphan

• Racemoramide

• Racemorphan

• [F3 Remifentanil]

• Sufentanil

• Thebacon

• Thebaine

• Tilidate

• Trimeperidine

• Zipeprol

• 4-Cyano-2-dimethylamino-4,4-diphenylbutane

• 4-Cyano-1-methyl-4-phenylpiperidine

• 2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid

• a-Methylphenethylhydroxylamine

• 1-Methyl-4-phenylpiperidine-4-carboxylic acid

• 4-Phenylpiperidine-4-carboxylic acid ethyl ester

Textual Amendments

F2 Word in Sch. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(2)(a)

F3 Word in Sch. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(2)(b)

2.  Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan. U.K.

3.  Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6. U.K.

4.  Any salt of a substance specified in any of paragraphs 1 to 3. U.K.

5.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5. U.K.

6.  The following substances and products, namely— U.K.

Acetyldihydrocodeine	Methaqualone
Amphetamine	Methylamphetamine
Codeine	Methylphenidate
Dextropropoxyphene	Nicocodine
Dihydrocodeine	Nicodicodine (6-nicotinoyldihydrocodeine)
Ethylmorphine (3-ethylmorphine)	Norcodeine
Fenethylline	Phenmetrazine
Glutethimide	Pholcodine
Lefetamine	Propiram
Mecloqualone	Quinalbarbitone

7.  Any stereoisomeric form of a substance specified in paragraph 6. U.K.

8.  Any salt of a substance specified in paragraph 6 or 7. U.K.

9.  Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5. U.K.

Regulation 3

SCHEDULE 3 U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15 (EXCEPT TEMAZEPAM), 16, 18, 22, 23, 24, 26 AND 27

1.  The following substances, namely— U.K.

(a)  

• Benzphetamine

• Buprenorphine

• Cathine

• Chlorphentermine

• Diethylpropion

• Ethchlorvynol

• Ethinamate

• Flunitrazepam

• Mazindol

• Mephentermine

• Meprobamate

• Methylphenobarbitone

• Methyprylone

• [F4 Midazolam]

• Pentazocine

• Phendimetrazine

• Phentermine

• Pipradrol

• Temazepam

(b) any 5, 5 disubstituted barbituric acid not being quinalbarbitone.

Textual Amendments

F4 Word in Sch. 3 para. 1(a) inserted (1.1.2008) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(3)(e), 4(14)

2.  Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine. U.K.

3.  Any salt of a substance specified in paragraph 1 or 2. U.K.

4.  Any preparation or other product containing a substance specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5. U.K.

Regulation 3

SCHEDULE 4 U.K.

PART I U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1.  The following substances and products, namely— U.K.

• Alprazolam

• Aminorex

• Bromazepam

• Brotizolam

• Camazepam

• Chlordiazepoxide

• Clobazam

• Clonazepam

• Clorazepic acid

• Clotiazepam

• Cloxazolam

• Delorazepam

• Diazepam

• Estazolam

• Ethyl loflazepate

• Fencamfamin

• Fenproporex

• Fludiazepam

• Flurazepam

• Halazepam

• Haloxazolam

• [F5 4-Hydroxy-n-butyric acid]

• [F6 Ketamine]

• Ketazolam

• Loprazolam

• Lorazepam

• Lormetazepam

• Medazepam

• Mefenorex

• Mesocarb

• F7 ...

• Nimetazepam

• Nitrazepam

• Nordazepam

• Oxazepam

• Oxazolam

• Pemoline

• Pinazepam

• Prazepam

• Pyrovalerone

• Tetrazepam

• Triazolam

• N-Ethylamphetamine

• [F8 Zolpidem]

Textual Amendments

F5 Words in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(a)

F6 Word in Sch. 4 Pt. 1 para. 1 inserted (1.1.2006) by The Misuse of Drugs (Amendment) (No. 3) Regulations 2005 (S.I. 2005/3372), regs. 1, 2

F7 Word in Sch. 4 Pt. 1 para. 1 omitted (1.1.2008) by virtue of The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(3)(e), 4(13)

F8 Word in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(b)

2.  Any stereoisomeric form of a substance specified in paragraph 1. U.K.

3.  Any salt of a substance specified in paragraph 1 or 2. U.K.

4.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5. U.K.

PART II U.K. CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON POSSESSION WHEN IN THE FORM OF A MEDICINAL PRODUCT; EXCLUDED FROM THE APPLICATION OF OFFENCES ARISING FROM THE PROHIBITION ON IMPORTATION AND EXPORTATION WHEN IMPORTED OR EXPORTED IN THE FORM OF A MEDICINAL PRODUCT BY ANY PERSON FOR ADMINISTRATION TO HIMSELF; AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1.  The following substances, namely— U.K.

• [F9 4-Androstene-3, 17-dione]

• [F9 5-Androstene-3, 17 diol]

• Atamestane

• Bolandiol

• Bolasterone

• Bolazine

• Boldenone

• Bolenol

• Bolmantalate

• Calusterone

• 4-Chloromethandienone

• Clostebol

• Drostanolone

• Enestebol

• Epitiostanol

• Ethyloestrenol

• Fluoxymesterone

• Formebolone

• Furazabol

• Mebolazine

• Mepitiostane

• Mesabolone

• Mestanolone

• Mesterolone

• Methandienone

• Methandriol

• Methenolone

• Methyltestosterone

• Metribolone

• Mibolerone

• Nandrolone

• [F10 19-Nor-4-Androstene-3, 17-dione]

• [F10 19-Nor-5-Androstene-3, 17 diol]

• Norboletone

• Norclostebol

• Norethandrolone

• Ovandrotone

• Oxabolone

• Oxandrolone

• Oxymesterone

• Oxymetholone

• Prasterone

• Propetandrol

• Quinbolone

• Roxibolone

• Silandrone

• Stanolone

• Stanozolol

• Stenbolone

• Testosterone

• Thiomesterone

• Trenbolone

Textual Amendments

F9 Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(a)

F10 Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(b)

2.  Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say - U.K.

(a) by further substitution at position 17 by a methyl or ethyl group;

(b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

(d) by fusion of ring A with a heterocyclic system.

3.  Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule. U.K.

4.  The following substances, namely— U.K.

Chorionic Gonadotrophin (HCG)

Clenbuterol

Non-human chorionic gonadotrophin

Somatotropin

Somatrem

Somatropin

5.  Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule. U.K.

6.  Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule. U.K.

7.  Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5. U.K.

Regulation 3

SCHEDULE 5 U.K. CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON IMPORTATION, EXPORTATION AND POSSESSION AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 24 AND 26

1.—(1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations. U.K.

(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.

F11 2.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . U.K.

Textual Amendments

F11 Sch. 5 para. 2 revoked (14.11.2005) by The Misuse of Drugs and the Misuse of Drugs (Supply to Addicts) (Amendment) Regulations 2005 (S.I. 2005/2864), regs. 1(1), 13

3.  Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health. U.K.

4.  Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations. U.K.

5.  Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin. U.K.

6.  Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate. U.K.

7.  Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose. U.K.

8.  Any powder of ipecacuanha and opium comprising— U.K.

• 10% opium, in powder,

• 10% ipecacuanha root, in powder, well mixed with

• 80% of any other powdered ingredient containing no controlled drug.

9.  Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug. U.K.

Regulation 19

SCHEDULE 6 U.K. FORM OF REGISTER

PART I U.K. Entries to be made in case of obtaining

Date on which supply received	Name	Address	Amount obtained	Form in which obtained
	of person or firm from whom obtained

PART II U.K. Entries to be made in case of supply

Date on which transaction effected	Name	Address	Particulars as to licence or authority of person or firm supplied to be in possession	Amount supplied	Form in which supplied
	of person or firm supplied

Regulation 28

SCHEDULE 7 U.K. REGULATIONS REVOKED

Regulations revoked	References
The Misuse of Drugs Regulations 1985	S.I. 1985/2066
The Misuse of Drugs (Amendment) Regulations 1986	S.I. 1986/2330
The Misuse of Drugs (Amendment) Regulations 1988	S.I. 1988/916
The Misuse of Drugs (Amendment) Regulations 1989	S.I. 1989/1460
The Misuse of Drugs (Amendment) Regulations 1990	S.I. 1990/2630
The Misuse of Drugs (Amendment) Regulations 1995	S.I. 1995/2048
The Misuse of Drugs (Amendment No. 2) Regulations 1995	S.I. 1995/3244
The Misuse of Drugs (Amendment) Regulations 1996	S.I. 1996/1597
The Misuse of Drugs (Amendment) Regulations 1998	S.I. 1998/882
The Misuse of Drugs (Amendment) Regulations 1999	S.I. 1999/1404

Regulations 8(8) and 9(8)

[F12 SCHEDULE 8 U.K.

Textual Amendments

F12 Sch. 8 inserted (15.10.2003) by The Misuse of Drugs (Amendment) (No. 3) Regulations 2003 (S.I. 2003/2429), reg. 1, Sch.

1.   Any of the following persons may supply or administer a specified controlled drug under a patient group direction, namely— U.K.

(a) a person who holds a certificate of proficiency in ambulance paramedic skills issued by, or with the approval of, the Secretary of State, or a person who is a F13 ... registered paramedic;

F14 (b) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(c) a registered midwife;

[F15 (d) a registered optometrist;

(e) a registered chiropodist;

(f) a registered orthoptist;

(g) a registered physiotherapist;

(h) a registered radiographer;]

[F16 (i) a registered occupational therapist;

(j) a registered orthotist and prosthetist;]]

Textual Amendments

F13 Word in Sch. 8 para. 1(a) revoked (16.8.2007) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(1), 4(16)(a)

F14 Sch. 8 para. 1(b) omitted (1.8.2004) by virtue of The Health Act 1999 (Consequential Amendments) (Nursing and Midwifery) Order 2004 (S.I. 2004/1771), art. 1(1), Sch. para. 24(d)

F15 Sch. 8 para. 1(d)-(h) substituted (16.8.2007) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(1), 4(16)(b)

F16 Sch. 8 para. 1(i)(j) inserted (7.7.2006) by The Misuse of Drugs (Amendment No. 2) Regulations 2006 (S.I. 2006/1450), regs. 2(1), 11 (with regs. 12, 13)